drugset / Trial / NCT05932524
Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia
Phase 2
Unknown
132 enrolled
Peking University People's Hospital
Beijing Friendship Hospital · collabBeijing Hospital · collabBeijing Luhe Hospital · collabBeijing Tsinghua Changgeng Hospital · collabChina-Japan Friendship Hospital · collabChinese PLA General Hospital · collabNavy General Hospital, Beijing · collabPeking University First Hospital · collabPeking University Third Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A randomized, open-label, multicenter, phase 2 trial to compare the efficacy and safety of baricitinib plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with primary immune thrombocytopenia (ITP).
Timeline
- Start
- 2023-07-07
- Primary completion
- 2024-06
- Completion
- 2025-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | 2 mg | Oral |
| Background | Dexamethasone | Small molecule | 40 mg | — |